# Sermorelin Research: The GHRH(1-29) and Cognition Evidence

> Sermorelin research, read straight: the GHRH-receptor mechanism, the GH/IGF-1 restoration in older men, and the GHRH-analog cognition trial (P=0.03), each finding logged to its source study.

From the pituitary receptor to the cognition signal — the mechanism cascade, the GH/IGF-1 data, and the cognition trial, each finding welded to its study.

## Before the details

This page walks the **sermorelin research** record from the inside out. Sermorelin switches on a receptor in the pituitary; that switch raises the body's own growth hormone in timed bursts; growth hormone raises IGF-1 in the liver; and a close relative of sermorelin moved a measure of thinking in older adults. Each step below is a real study with a real number. Where the evidence is strong (growth-hormone release, IGF-1 rise) it says so; where it is thin or comes from a different analog (anti-aging, fat loss), it says that too — plainly, not buried.

## The mechanism cascade: receptor to IGF-1

Sermorelin's activity is a defined chain of events. It binds the GHRH receptor on anterior-pituitary somatotrophs, activating Gs / adenylate cyclase / cAMP / protein kinase A signaling [11]. That raises growth-hormone gene transcription and releases stored growth hormone in a pulse; growth hormone then drives hepatic IGF-1 production through the GH/IGF-1 axis [11].

The loop closes itself. Growth hormone exerts autofeedback on the response to GHRH, with free fatty acids and somatostatin involved, so the system damps its own output [13]. Somatostatin — the opposing "brake" hormone — and IGF-1 both feed back to keep secretion physiologic. This preserved feedback is the mechanistic basis for the claim that sermorelin works with the body's controls rather than against them.

Delivery pattern shapes the response. In normal men, pulsatile administration of GHRH preserved growth-hormone responsiveness relative to a continuous infusion [12] — evidence that the pituitary reads the rhythm of the signal, not just its presence. The native peptide's brevity (a ~10-12 minute IV plasma half-life) means a single dose acts as a discrete pulse [3].

## GH and IGF-1 in older men: the clearest adult datum

The Corpas study is the load-bearing adult finding. In healthy old men (mean 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour growth hormone and IGF-1. After high-dose treatment, GH/IGF-1 parameters no longer differed from those of young men — an age-related decline effectively reversed over two weeks — with no effect on fasting glucose [2].

This is a small, short study (n=10 old, n=9 young), and it measures hormone levels, not health outcomes. But it cleanly demonstrates the upstream premise: prompting the pituitary in older adults restores the GH/IGF-1 axis toward a younger profile, within the physiologic range, under intact feedback [2].

## Pharmacokinetics: fast in, three hours of effect

In 30 healthy men, intravenous GHRH(1-29)NH2 elicited significant growth-hormone release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg. Despite rapid elimination, growth hormone remained elevated for about 3 hours after a single dose — the pulse outlasts the peptide [3]. Intranasal bioavailability was only 3-5%, which is why mucosal and oral routes are poorly regarded for a peptide this fragile [3].

The short half-life is the engineering problem the field set out to solve. Substitutions such as D-Ala2 and albumin-binding DAC technology were developed specifically to extend GHRH activity into longer-acting analogs [3][14].

## Sermorelin and cognition in older adults

The cognition thread is the dealt lens of this board, and it runs through GHRH-analog trials. In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), increased IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%; adverse events were mild [6]. An earlier controlled study had already reported that growth hormone-releasing hormone improved the cognition of healthy older adults [9].

The effect has a neurochemical correlate: GHRH administration changed brain gamma-aminobutyric acid (GABA — a major inhibitory neurotransmitter) levels in mild cognitive impairment and healthy aging, alongside its cognitive effects [8]. Observational data point the same way — in adults who received cranial radiotherapy for brain tumors, peak growth hormone from a standardized GHRH-arginine test correlated positively with working-memory and visual long-term-memory performance, and the GH-deficient patients performed worse on attention and interference-control tasks [7]. A 2025 Nature Reviews Endocrinology synthesis frames the broader GHRH-analog landscape [14], and 2026 preclinical work reported that GHRH attenuated amyloid deposition and neuroinflammation with improved cognitive performance in Alzheimer's-disease models [15].

## Sermorelin vs tesamorelin

Worth stating plainly, because the cognition and body-composition trials above used tesamorelin, not native sermorelin. Sermorelin is native GHRH(1-29); tesamorelin is a stabilized GHRH analog (FDA-approved for HIV-associated lipodystrophy) engineered for a longer duration of action [14]. Both act at the GHRH receptor, but the human cognition (P=0.03) and visceral-fat (-7.4% body fat) data come from tesamorelin trials [6]. Reading those results onto sermorelin is a mechanistic inference, not a like-for-like result — a distinction this board keeps visible rather than blurring.

## Sermorelin and body composition

GHRH-axis stimulation can change body composition. The clearest data again come from the stabilized analog: in the 152-person trial, tesamorelin reduced percent body fat by 7.4% versus placebo [6], and the analog's approved indication is HIV-associated visceral fat accumulation [14]. For native sermorelin in healthy adults, controlled body-composition evidence is limited, and **sermorelin weight loss** claims in marketing outrun the rigorous data [5].

## Does sermorelin affect the brain?

Yes — GHRH and its analogs reach the brain's GH/IGF-1 axis. Randomized trials of a GHRH analog changed cognition and brain GABA levels in older adults [6][8], and preclinical GHRH-agonist work reduced amyloid-beta and improved cognition in Alzheimer's-disease models [15]. These are research findings on the GHRH pathway, not a treatment recommendation.

## Can sermorelin or GHRH improve cognition in older adults?

A 152-person randomized, placebo-controlled trial of a daily GHRH analog reported a favorable effect on cognition (P=0.03) over 20 weeks [6], and an earlier controlled study reported improved cognition in healthy older adults [9]. These are research findings, not a treatment recommendation, and the larger trial used the analog tesamorelin rather than native sermorelin.

## Does sermorelin work?

In its approved pediatric use it accelerated growth in growth-hormone-deficient children [1], and in older men twice-daily GHRH(1-29) raised 24-hour growth hormone and IGF-1 [2]. Broader adult anti-aging efficacy is not established; an Annals of Internal Medicine editorial called secretagogue use for aging "not yet ready for prime time" [5].

## How long does it take for sermorelin to work?

Single doses raise growth hormone within hours — GH stayed elevated about 3 hours after an IV dose [3] — while measurable GH/IGF-1 changes in studies followed days to weeks of repeated dosing (for example, 14 days in older men) [2]. These are study observations, not a protocol.

## How does sermorelin compare to CJC-1295?

Both act on the GHRH receptor, but native GHRH(1-29) is short-lived (~10-12 minute IV half-life) [3]. The D-Ala2 substitution and DAC albumin-binding technology behind CJC-1295 were developed specifically to extend that half-life into a longer-acting analog [3][14].

## Does sermorelin burn fat?

GHRH-axis stimulation can change body composition — the stabilized GHRH analog tesamorelin significantly reduced visceral fat (percent body fat -7.4%) versus placebo [6] — but anti-aging and body-composition marketing for sermorelin in healthy adults outpaces the rigorous evidence [5].

## Is sermorelin effective for weight loss?

There is no robust evidence that sermorelin causes weight loss in healthy adults. The body-composition effects in the literature come largely from GHRH-analog studies in specific clinical populations [6], and those findings should not be generalized as a weight-loss treatment [5].

## Will sermorelin raise my IGF-1 levels?

In older men, GHRH(1-29) twice daily produced dose-related increases in 24-hour growth hormone and IGF-1, with high-dose values no longer differing from those of young men [2]. IGF-1 also provides negative feedback that helps keep the rise within a physiologic range [13].

## Does sermorelin build muscle?

Sermorelin raises growth hormone and IGF-1 [2], hormones involved in lean tissue, and GH/IGF-1-axis modulation has been discussed as a strategy against age-related muscle loss [10]. Direct controlled evidence that sermorelin builds muscle in healthy adults is limited.

## How does sermorelin differ from direct HGH injections?

Direct HGH supplies exogenous growth hormone and overrides normal control, whereas sermorelin acts upstream on the pituitary, so somatostatin and IGF-1 feedback remain intact and the body's pulsatile pattern is preserved [11][13]. An editorial argues this upstream route is a more physiologic approach to adult-onset growth-hormone insufficiency [4].

## Sermorelin before and after: what changes do studies report?

Documented changes include accelerated height velocity (~4.1 → ~7-8 cm/year) in growth-hormone-deficient children [1], dose-related rises in 24-hour growth hormone and IGF-1 in older men [2], and — for the related analog tesamorelin — reduced body fat (-7.4%) and a favorable cognition signal (P=0.03) [6]. These are population-specific research outcomes, not a personal before/after promise.

---

A constructivist reading board for the sermorelin record — every GHRH(1-29) figure logged to its study and the empty long-term adult-evidence members left openly unfilled; sermorelin was a medicine, is read here as research, and nothing on this board is dispensed, prescribed, or sold.